anti_endometrial Antibodies in Endometriosis

South Valley University

Status: Active, not recruiting

Conditions: Anti-endometrial Antibodies

Treatments: Diagnostic Test: serum anti-endometrial antibodies

Study type: Observational

Funder types: Other

Identifiers

NCT05851352

anti_endometrial antibodies

Details and patient eligibility

About

The aims of this study is to asses the predictive value of serum anti_endometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles.

Full description

prospective cohort study of infertile patients ( with endometriosis & adenomyosis) who will undergo ICSI cycles at the assisted reproduction units,Obstetrics and Gynacology departments , South Valley University and Cairo University.

Initial evaluation: this will include:

1. Detailed history and clinical examination.

2. Ovarian reserve testing (serum AMH , basal serum FSH and basal AFC by US)

3. Uterine cavity examination ( by trasvaginal 3-dimentional ultrasound or office hysteroscopy)

4. routine investigations (Complete blood count, blood grouping , liver function tests , kidney function tests , prothrombin time , prothrombin concentration , serum bloog sugar)

5. Evaluation of male factor (husbnad semen analysis)

   • Eligible women will undergo :

     • Transvaginal ultrasound for evaluation of endometriosis ( shape , size , unilateral or bilateral , unilocular or bilocular )
     • Perform laparscopy for confirmation of endometriosis using revised ASM classification for endometriosis
     • Measurement of serum anti_endometrial antibodies :
     • Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .

Intracytoplasmic sperm injection (ICSI) gonadotrophin stimulation drugs will be used, individualization of stimulation dose and slight modifications will be done according to ovarian response. Proper protocol will be used. Baseline assessment of AFC by transvaginal scans wasill be performed by experienced gynaecologist using a 7.5 MHz vaginal probe 7-MHz (Samsung, Korea). Ovarian response monitoring to stimulation drug, estimation the doses of gonadotrophins required for follicular growing and maturation, assessment the stimulation time in days till time of ovum pick-up, and the number and quality of oocytes obtained will be recorded in and analysed at the end of the study. When 3-4 follicles acquired >18 mm ,triggering of ovulation will be done using human chorionic gonadotrophins 36 hours prior to pick-up of oocytes. after oocyte retrieval ICSI procedure will be done for all cases. embryos will be transferred to each mother on day 3 or day 5 according to embryos quality and remaining of good quality embryos will be frozen for subsequent transfer. Luteal support started in day of ova pick up till date of pregnancy test (14 days post embryos transfer)

Research outcome measures:

a. Primary (main):

• assess the predictive value of serum antiendometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles b. Secondary (subsidiary):
• to find correlation between serum anti-endometrial antibodies and egg quality retrieved

Enrollment: 30 estimated patients

Sex: Female

Ages: 15 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients will be enrolled in this study if they fulfill the following criteria:

1. infertile patients (with endometriosis & adenomyosis ) who will undergo ICSI cycles

2. Age: 18-35 years.

3. Body mass index (BMI): ≤ 30.

4. primary or secondary infirtility. 5 duration of infertility less than 10 years

5. results of semen examination of patients' husbands will be within the World Health Organization (WHO) reference range.

Exclusion criteria

Patients will not be eligible for this study if:

1. gynecological problem e.g. uterine polyp, hydrosalpinx will be excluded 2. Male factor: Abnormal sperm morphology;(globozoospermia and pin- point sperm) will be excluded 3 . congenital structural abnormalities of the reproductive tract, pelvic tuberculosis, ovarian tumour, hyperprolactinaemia, adrenal disease, thyroid disease or other endocrine disease,